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BACKGROUND: COPD is characterized by expiratory flow limitation, which results in symptom-
atic dyspnea and reduced exercise capacity. Changes in breathing mechanics mean the respiratory
muscles are unable to respond to the ventilatory demands, increasing the sensation of dyspnea. A
high-frequency oscillating device has been developed to improve dyspnea in patients with COPD.
We conducted a feasibility trial to gain insight into the potential for recruitment, retention, and study
design for a future randomized controlled trial. METHODS: Symptomatic subjects with COPD were
included on the basis of a Medical Research Council (MRC) score > 3 and FEV1/FVC < 0.70).
Patients were excluded if they received pulmonary rehabilitation within the last 6 months. The
intervention employed the device for 8 weeks, 3 times daily. Clinical outcomes included the MRC
score, maximal expiratory and inspiratory pressures (PEmax/PImax), the incremental shuttle walk
test (ISWT), and the endurance shuttle walk test (ESWT). RESULTS: We successfully recruited
23 subjects with established COPD (65.2% male, mean age 65  5.03 y, mean % predicted FEV1
43.9  16, mean FEV1/FVC ratio 0.46  0.13, and median [interquartile range] MRC 4 [3–5]).
There was a significant change in MRC from 4 to 3 pre to post intervention (P  .003). There was
a statistically significant difference in PEmax P < .008 and PImax P  .044. There were no significant
differences observed in the ISWT or ESWT. CONCLUSIONS: This study design appeared feasible
to proceed to a clinical effectiveness trial. The use of the device for 8 weeks showed a significant
improvement in PEmax, PImax, and reducing symptomatic dyspnea on the MRC dyspnea score. The
results of this study should encourage a randomized controlled trial. Key words: breathing exercises;
pulmonary disease; COPD; dyspnea; respiratory muscles; positive-pressure respiration. [Respir Care
0;0(0):1–•. © 0 Daedalus Enterprises]
Introduction
COPD is characterized by expiratory flow limitation,
which results in excessive dyspnea and reduced exercise
capacity. Dyspnea is a multidimensional symptom and may
be a result of the muscles of respiration being unable to
meet the demands of the mechanical load and capacity,
causing respiratory muscle dysfunction and the sensation
of dyspnea. Longstanding dyspnea can result in reduced
exercise capacity and impaired quality of life.1 A method
of therapy for the management of dyspnea is inspiratory
muscle training, which is frequently used in the COPD
population.2
The benefits of inspiratory muscle training have been
identified in several randomized controlled trials and sum-
marized in a systematic review by Gosselink et al.2 Key
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benefits are believed to be increased inspiratory muscle
strength and endurance, functional exercise capacity, and
health-related quality of life when compared to a control
group; these improvements appear meaningful in terms of
quality of life, dyspnea, and muscle strength.2-5 This meta-
analysis explores randomized controlled trials using in-
spiratory muscle training programs at 30% of their max-
imum. In addition, high-intensity inspiratory muscle
training, identified as training at 50% of a subject’s max-
imum, has been shown to improve inspiratory muscle func-
tion in those with moderate to severe COPD.6 Research
has also suggested that long-term inspiratory muscle train-
ing can decrease the use of health services and reduce
hospital length of stay.7 Differences among training pro-
tocols and subsequent variances in results make this treat-
ment difficult to implement and generalize.
Combined respiratory muscle training (RMT) is an ad-
ditional technique for the management of dyspnea, although
this therapy has been used less frequently despite the ad-
ditional benefit of training expiratory muscles. It has been
suggested that up to 50% of individuals with moderate to
severe COPD exhibit expiratory muscle weakness in par-
allel with inspiratory muscles.8 While there is a limited
evidence base for combined inspiratory and expiratory mus-
cle training, it has been shown to improve respiratory mus-
cle strength and endurance with an increase in the 6-min
walk distance compared with inspiratory muscle training
alone.9 Reference values for maximum expiratory pressure
(PEmax) have been discussed, but there has been no defin-
itive categorization of expiratory muscle weakness. As a
result it is difficult to identify patients who may benefit
from combined respiratory muscle training. The mecha-
nisms and effectiveness of RMT have been a topic for debate
and are not fully accepted as a method to manage COPD. The
joint American College of Chest Physicians/American Asso-
ciation of Cardiovascular and Pulmonary Rehabilitation
Committee declared that a stimulus or load applied to the
respiratory muscles during training is sufficient to aug-
ment respiratory muscle strength and is associated with
increased exercise capacity and decreased dyspnea. How-
ever, the National Institute for Clinical Excellence does
not yet recommend RMT in COPD management due to a
disparity in the research.10,11
The Aerosure Medic (Aerosure, Bracknell, United King-
dom) is a flow-resistive device designed to offer resistance
on inspiration and expiration with the aim to reduce dys-
pnea by improving breathing efficiency. The device also
offers oscillations for mucociliary clearance, which may
assist with reducing dyspnea by addressing air-flow ob-
struction.12 The combination of RMT and mucociliary
clearance may contribute further to the management of
dyspnea. This study assesses a number of outcomes in-
cluding dyspnea, cough frequency, and sputum clearance
to provide quantitative data on the use of a RMT device,
which will inform and refine the potential for a clinical
effectiveness trial. The objectives of this study were to (1)
to assess the recruitment rate of participants and eligibility
in regards to the inclusion and exclusion criteria and gain
insight into dropout rates of the training program; (2) to
explore device adherence and the training program; (3) to
assess a number of outcomes and understand their feasi-
bility in the use of a large clinical effectiveness trial; and
(4) to explore and establish a primary outcome measure
for the design of a clinical effectiveness trial and give
insight into the sample size necessary.
Methods
This was a feasibility study designed to investigate
the use of an RMT device to inform the clinical effec-
tiveness of a randomized controlled trial. Ethical ap-
proval was obtained by the London Central National
Health Service Health Research Authority and the Local
Research Ethics Committee. The ISRCTN trial number
is ISRCTN81979106.
Participant Selection
Twenty-four symptomatic subjects with COPD were re-
cruited from the pulmonary rehabilitation database at the
University Hospitals of Leicester. The sample size was
pragmatic and was deemed to be appropriate to assess the
feasibility of a clinical effectiveness trial. Subjects were
included if they had stable COPD and a Medical Research
Council (MRC) dyspnea score of  3. Patients were ex-
cluded if they had completed pulmonary rehabilitation
within the last 6 months. A diagnosis was confirmed by
spirometry measures as outlined by the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) 2011 stan-
dards (FEV1/FVC ratio  0.70).13
QUICK LOOK
Current knowledge
Respiratory muscle dysfunction can contribute to pro-
gressive dyspnea. Inspiratory muscle training has been
shown to be effective in reducing dyspnea and improv-
ing inspiratory muscle strength in patients with COPD.
What this paper contributes to our knowledge
The use of high-frequency airway oscillations improved
inspiratory and expiratory muscle strength resulting in
an improvement in dyspnea. This should encourage a
future randomized controlled trial.
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The clinical outcomes for the study were the MRC dys-
pnea score, PEmax, and inspiratory pressure (PImax), performed
in line with the American Thoracic Society/European Re-
spiratory Society statement.14 PEmax was tested from total
lung capacity, and PImax was tested from residual lung
volume. Each test was performed in an upright sitting
position. Subjects were instructed to perform the maneu-
ver maximally and to sustain for a minimum of 2 s. The
test was performed a minimum of 4 times and up to
7 times if the subject continued to improve within the
accepted tolerance, which was performed by a trained
professional to optimize volitional effort. The incremental
shuttle walk test (ISWT) and endurance shuttle walk test
(ESWT) were performed according to the American Tho-
racic Society/European Respiratory Society guidelines,
which include a familiarization ISWT to account for a
learning effect.15 The COPD Assessment Test and the
Chronic Respiratory Questionnaire were used as a health-
related quality-of-life measure. The Leicester Cough Ques-
tionnaire, London Activity of Daily Living Questionnaire,
and the Hospital Anxiety and Depression Scale were also
used. Questionnaires were completed by each subject with
supervision before and after intervention. A post-trial event
was held to discuss the results and to secure feedback on
the proposed future trial design.
Device
The intervention used a high-frequency oscillating de-
vice (Aerosure Medic, Actegy, Bracknell, United King-
dom), which provided flow resistance and oscillations. This
was a battery-operated, dual-action device providing os-
cillations at 25 Hz, and resistance was provided in relation
to the subject’s flow. Subjects were instructed to use the
device for 5 min, 3 times per day, performing deep max-
imal breathing. The intervention was used for a period of
8 weeks with the use of a self-reported diary and weekly
telephone calls to monitor adherence and manage any de-
vice-related issues. All subjects were instructed to use the
device for the period of the intervention phase and were
allowed to keep the device upon completion of the trial.
Statistical Analysis
Data were analyzed using SPSS version 24 (IBM, North
Castle, New York). The Wilcoxon signed-rank test was
used because the data were non-parametric for all vari-
ables. Subjects were considered adherent if they completed
75% of the training protocol, as recorded in the self-re-
ported diary. PImax was considered weak if60 cm H2O
as reported in the literature.2 Because no reference val-
ues are available for PEmax, this was calculated based on
the Evans formula to calculate the lower limit of nor-
mal: PEmax for males  117  (0.83  age); PEmax for
females  95  (0.57  age).16 Results were consid-
ered statistically significant if P  .05. A sub-group
analysis was performed on subjects with poor inspira-
tory muscle strength ( 60 cm H2O) compared to
those with normal inspiratory muscle strength ( 60 cm
H2O).
Results
Of 39 patients originally screened for eligibility, 24
(61.5%) subjects were initially recruited. One subject was
excluded after normal spirometry during the first visit.
With 59% of the initially identified patients being eligible
for recruitment, the inclusion and exclusion criteria were
deemed appropriate. There was a dropout rate of 13% and
a self-reported adherence rate of 90% of subjects who met
the minimum training requirement of 75% (Figure 1).
Baseline Characteristics
Baseline characteristics are shown in Table 1. The co-
hort was predominantly categorized as moderate, GOLD13
stage II, with a median MRC score of 4 (interquartile
range [IQR] 3.00–4.75). Participants were managed with
a combination of inhaled therapies, commonly triple ther-
apy (ie, a combination of long-acting muscarinic antagonist,
long-acting agonist, and inhaled corticosteroids). Mean (SD)
PImax values were 57.48  26 cm H2O (PImax  60 cm
H2O qualified as inspiratory muscle weakness).2 Based on
the Evans calculations, 7 subjects demonstrated expiratory
Fig. 1. Flow chart.
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muscle weakness ranging from 41.33% to 88.64% of pre-
dicted values.16
Of the 23 enrolled subjects, 1 subject was withdrawn
due to ill health, 1 subject was withdrawn for social rea-
sons, and 1 subject stopped using the device due to an
adverse event where the participant experienced unex-
plained vocal cord irritation. Therefore, 20 subjects were
included in the analysis.
Intervention
After the 8-week intervention, data were collected on
20 subjects. Exercise test and respiratory muscle function
data were completed on 19 of the participants. Overall,
subjects improved their MRC score from 4 to 3 (P .003,
95% CI 2.68–3.32). Subjects’ median (IQR) PImax im-
proved from 59 cm H2O (34–74) to 63 cm H2O (42–
85) (P  .044). PEmax improved from a median (IQR) of
102 (62–125) to 110 (97–137) (P  .003), which was
statistically significant. No statistical or clinically mean-
ingful change in exercise performance (ISWT or ESWT),
Chronic Respiratory Questionnaire, Hospital Anxiety and
Depression Scale, or London Activity of Daily Living
Questionnaire were observed. A change in COPD
Assessment Test score was seen (mean differ-
ence  0.95  4.62) but this was not clinically mean-
ingful (Table 2).17 Sub-group analysis demonstrated a
greater improvement in PImax and ISWT in those with in-
spiratory muscle weakness ( 60 cm H2O) (Figure 2)
(Table 3).
Discussion
The results of this study demonstrate appropriate eligi-
bility criteria, a low dropout rate, and high adherence to
the training protocol; we therefore believe that this study
design is appropriate and a larger randomized, controlled
trial is deemed feasible. This study design demonstrates a
high enrollment rate; while most potentially eligible par-
ticipants were screened out due to current exacerbation,
these patients were enthusiastic about treatment and it is
likely that with an extended recruitment period we may be
able to enroll these patients when they are stable (ie, no
exacerbation in the last 4 weeks). The retention rate was
high, with a 13% dropout rate, which is equal to or less
than the attrition of similar study designs, suggesting that
the training program was not too burdensome.
The use of the device for 8 weeks resulted in significant
improvement in respiratory muscle strength and dyspnea,
demonstrated by inspiratory and expiratory pressures and
reduced MRC score, despite not intentionally recruiting
Table 2. Pre and Post Intervention
Pre Intervention,
Median (IQR)
Post Intervention,
Median (IQR) P
MRC 4 (3–5) 3 (3–3) .003
PImax, cm H2O 59 (34–74) 63 (42–85) .044
PEmax, cm H2O 102 (62–125) 110 (97–137) .008
ISWT, m 200 (140–260) 240 (170–270) .68
ESWT, s 170.5 (130.5–246.75) 203 (142.25–274.25) .51
CRQ dyspnea 2.6 (2.0–2.8) 2.5 (2.05–3.70) .32
CRQ total 16.97 (12.91–18.12) 16.7 (14.77–19.63) .85
LCQ total 15.71 (12.66–19.36) 21.5 (16.25–25.50) .14
HADS anxiety 6 (3–10) 6 (3.25–11.25) .24
HADS depression 6 (4–10) 5 (4–7.5) .19
LCADL total 32 (28–45) 29 (23.25–39) .26
CAT total 24 (18–29) 21.5 (16.25–25.5) .14
CAT sputum 3 (2–4) 3 (2–3.75) .76
N  20, N  19
IQR  interquartile range
MRCMedical Research Council Score
PImax  maximum inspiratory pressure
PEmax  maximum expiratory pressure
ISWT  incremental shuttle walking test
ESWT  endurance shuttle walking test
CRQ  Chronic Respiratory Questionnaire
LCQ  Leicester Cough Questionnaire
HADS  Hospital Anxiety and Depression Score
LCADL  London Chest Activity of Daily Living
CAT  COPD assessment test
Table 1. Baseline Characteristics
Age, y 65  5.03
Male, % 65.2
Inhaled therapies
LABA or LAMA 3
LAMA/ICS 2
ICS/LABA LAMA 15
MRC, median (IQR) 4 (3.00–4.75)
GOLD stage
I 0
II 9
III 10
IV 4
FEV1, % predicted 43.9  16
PImax, cm H2O 57.48  26
PEmax, cm H2O 93.61  33
ISWT, m 217 118
ESWT, s 206 112.5
N  23
Values are baseline mean  SD unless otherwise noted. GOLD staging is presented as
numerical format and percentage per stage.
LABA  long-acting  agonist
LAMA  long-acting muscarinic antagonist
ICS  inhaled corticosteroids
MRCMedical Research Council Score
IQR  interquartile range
GOLD  Global Initiative for Chronic Obstructive Lung Disease
PImax  maximum inspiratory pressure
PEmax  maximum expiratory pressure
ISWT  incremental shuttle walk test
ESWT  endurance shuttle walk test
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participants with respiratory muscle weakness. Subjects
with reduced inspiratory muscle strength demonstrated a
greater improvement in dyspnea and respiratory muscle
strength. While we observed an improvement in the ISWT
and the ESWT, this was not statistically significant. There
was a notable difference between GOLD severity and MRC
dyspnea score at baseline, but as a result of the subjectivity
of dyspnea and the inability of the MRC score to capture
its complexity, this is unsurprising.18
The public and subject involvement allowed for insights
into the training intensity and use of the device as well as
a detailed understanding of how this affected dyspnea. It
was useful to assist with the design of a clinical effective-
ness trial and identified areas that had to be addressed (eg,
diary cards, training intensity, and follow-up calls). A power
calculation was performed based on the change in COPD
Assessment Test score, and 84 subjects will be required
for a randomized controlled trial. All outcome measures
were deemed appropriate by the subjects to assess the
effects of the device.
Dyspnea is the most common complaint for patients
with COPD.1 It has been reported that respiratory muscle
weakness is uncommon in patients with COPD, however
the function of these subjects demonstrated that both in-
Fig. 2. A: PImax inspiratory muscle pressures measured at the mouth. B: PEmax expiratory muscle pressures measured at the mouth. C:
Incremental shuttle walk test (ISWT) measured pre- and post-8 week intervention phase. D: Endurance shuttle walk test (ESWT) measured
pre- and post-8 week intervention phase.
Table 3. Comparison Between Participants Classified With Inspiratory Muscle weakness
Poor Inspiratory Muscle
Strength ( 60 cm H2O), n  9
Normal Inspiratory Muscle
Strength ( 60 cm H2O), n  10
Pre Intervention,
Median (IQR)
Post Intervention,
Median (IQR) P
Pre Intervention,
Median (IQR)
Post Intervention,
Median (IQR) P
MRC 4 (3–5) 3 (3–3) .02 4 (3–4) 3 (2–3) .058
PImax, cm H2O 35 (31–49) 42 (39–56) .050 74 (63–86) 77 (70–93) .14
PEmax, cm H2O 77 (57–102) 105 (83–111) .36 118 (108–134) 125 (109–159) .059
ISWT, m 150 (100–245) 200 (160–260) .064 250 (180–290) 265 (185–283) .44
ESWT, s 200 (120–278) 285 (104–376) .67 156 (134–190) 179 (144–224) .11
MRCMedical Research Council Score
PImax  maximum inspiratory pressure
PEmax  maximum expiratory pressure
ISWT  incremental shuttle walking test
ESWT  endurance shuttle walking test
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spiratory and expiratory muscles can be classified as weak,
similar to findings of a number of other trials exploring
RMT in COPD.2 This study did not select subjects on the
basis of respiratory muscle weakness, but sub-group anal-
ysis indicates that those classified as weak had greater
improvements in inspiratory muscle strength and ISWT,
and both groups significantly improved dyspnea scores,
therefore both groups will be included in the randomized
controlled trial. Furthermore, the threshold for weakness
appears to be arbitrary and does not account for an in-
creased ventilatory demand as associated with patients with
COPD. In addition, inspiratory muscle weakness has been
associated with hyperinflation-induced diaphragm short-
ening and fiber shift toward oxidative type-1 fibers in the
diaphragm of patients with COPD.8 Although less is un-
derstood regarding expiratory muscle weakness, it has been
suggested that 50% of patients with moderate to severe
COPD exhibit expiratory muscle weakness in parallel with
inspiratory muscles.2 Reference values for PEmax have been
discussed, although there is no definitive conclusion of
values that categorize expiratory muscle weakness.
The implementation of RMT is inconsistently applied in
the COPD population, and there is a need for rigorous
trials investigating this treatment.2 There is a large body of
evidence for the evaluation of inspiratory muscle training,
but differences in training protocols make it difficult to
reach consensus, which limits clinical application. Expi-
ratory muscle training has been shown to improve respi-
ratory function when used in combination with inspiratory
muscle training or oscillation for patients with mild to
severe COPD.19 In this study, we proposed an 8-week
training program of combined inspiratory and expiratory
muscle training using a device 3 times per day to provide
flow resistance and additional oscillations.
We did not see an important increase in exercise capac-
ity, which conflicts with other research; however, this de-
vice was not used in conjunction with any other form of
training or pulmonary rehabilitation, which may explain
the results. It is possible that these participants saw im-
provements in dyspnea and respiratory muscle strength
that did not translate into increased exercise capacity but
may have improved the quality of exercise, which was not
measured in this study. There are numerous other factors
that may limit exercise capacity, such as reduced energy
supply, leg discomfort, or comorbidities such as osteoar-
thritis, which may affect exercise capacity over time and
influence the results.20 There were 2 recorded exacerba-
tions during the follow-up period, which also may have
affected exercise capacity.
Limitations
This single-arm study was devised to explore the feasi-
bility of using an RMT device with COPD. This study has
a small sample size and therefore is not generalizable to
the COPD population; this research, however, has shown
a reduction in dyspnea. This single-arm, non-blinded study
may be subject to bias. In the absence of a control group,
it is not possible to make any comment on clinical effec-
tiveness at this stage because we are unable to rule out the
potential of a placebo effect. While sub-group analysis
may allow for some indication of population groups that
may benefit from this device, this should be interpreted
with caution due to the small sample size.
The device used in this study does not have the function
to increase or reduce resistance and therefore may not be
suitable for all patients with COPD; however, the device
was accepted by the subjects and does not allow the sub-
jects to make adjustments outside of the protocol.
Conclusions
The aim of this study was to explore the feasibility of
designing a clinical effectiveness trial investigating the use
of a high-frequency oscillation device in the management
of dyspnea in COPD. The eligibility criteria enabled a
suitable recruitment rate with a dropout of 13%, which
included subjects who were unable to complete the fol-
low-up testing. The training intensity seems feasible with
an adherence rate of 90% among subjects. Subjects of this
cohort demonstrated a significant increase in PEmax and
PImax as well as a subsequent statistically significant re-
duction in dyspnea. This study provides encouraging re-
sults in reducing dyspnea with combined RMT with Aero-
sure device.
Outcome measures assessed the identified implications
of using the device and therefore will assist with the future
trial design. Public and subject involvement identified ar-
eas that may need to be addressed prior to a large clinical
effectiveness trial. The results of this study should encour-
age a full randomized controlled trial.
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